Invesco’s AC Immune ACIU Stock Holding History

Invesco’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-17,362	Closed	-$65.6K	–	3757
2024 Q3	$65.6K	Buy	17,362 +5,471	+46%	+$19.1K	﹤0.01%	3657
2024 Q2	$47.4K	Buy	+11,891	New	+$39.3K	﹤0.01%	3828

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco's ACIU Position: Q4 2024 in Review

Invesco sold out of AC Immune (ACIU) in Q4 2024, closing a stake of 17,362 shares — an estimated $65.6K sold.

Invesco first reported a position in ACIU in Q2 2024 and held it in 2 quarters. The position peaked at $65.6K in Q3 2024. 45 funds tracked by Wall St. Rank hold ACIU as of Q4 2024.

Invesco reported no remaining AC Immune position as of Q4 2024 after selling out during the quarter.
Invesco sold 17,362 AC Immune shares in Q4 2024, an estimated $65.6K.
Invesco first reported a position in AC Immune in Q2 2024 and held it in 2 quarters.
Invesco's AC Immune position peaked at $65.6K in Q3 2024.
45 funds tracked by Wall St. Rank held AC Immune as of Q4 2024.

Based on Invesco's 13F filing for Q4 2024, filed 13 Feb 2025.